ELAB vs STT · rev $2.0M vs P/E 17, rev $7.84B
Elevai Labs, Inc. Common Stock (ELAB) versus State Street Corp (STT) — a side-by-side from cached financials, not a winner call.
Elevai Labs, Inc. Common Stock (ELAB) is a biotechnology company listed on NASDAQ.
State Street Corp (STT) is a asset management company listed on US.
Latest reported ELAB revenue for 2026-06-30 was $2.0M. Net income was -$7.9M. ELAB currently screens at market cap $6.5M.
Latest reported STT revenue for 2026-06-30 was $7.84B. Net income was $1.85B. STT currently screens at market cap $45.02B and trailing P/E 16.5.
ELAB currently screens at market cap $6.5M. STT currently screens at market cap $45.02B and trailing P/E 16.5.
Not investment advice. Open the ELAB and STT stock pages for the full models.
Not investment advice.